Sleep & GH

CJC-1295 (No DAC)

Modified GRF 1-29, Mod GRF 1-29, Sermorelin analog, GRF(1-29)NH2

CJC-1295 without DAC (Modified GRF 1-29) is a modified fragment of GHRH that produces a short, pulsatile GH signal closely mimicking the natural GHRH stimulus. Combined with a GHRP, it produces synergistic GH pulses 2–10x larger than either compound alone.

Subcutaneous (SubQ) Beginner Friendly
Save
This peptide profile is for research and educational purposes only. Not intended for human use or self-administration.

Overview

CJC-1295 without DAC, commonly called Modified GRF 1-29 (Mod GRF 1-29), is a modified fragment of the first 29 amino acids of naturally occurring Growth Hormone Releasing Hormone (GHRH). Four substitutions were made to the original GHRH(1-29) sequence to increase its resistance to enzymatic degradation while preserving a short half-life that closely mimics the natural pulsatile GHRH signal. This makes it the ideal GHRH analogue for combining with a GHRP like ipamorelin — together, they replicate the synergistic dual-signal that the pituitary uses to release a robust natural GH pulse.

Mechanism of Action

CJC-1295 without DAC binds to and activates the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. GHRH receptor activation triggers intracellular cAMP production and calcium influx, which directly stimulates growth hormone synthesis and secretion. When combined with a GHRP (which simultaneously inhibits somatostatin and activates the ghrelin receptor), the dual stimulation produces a GH pulse 2–10 times larger than either compound alone — this synergy is the pharmacological basis for the classic GHRH + GHRP combination. Because Mod GRF 1-29 has a short half-life (~30 minutes), it produces a sharp, clean GH pulse that quickly clears, allowing the axis to reset and preventing the receptor desensitization that occurs with continuous GHRH stimulation (as seen with the DAC version).

Key Research

Modified GRF 1-29 was developed based on the original GHRH(1-29) structure with four substitutions to increase enzymatic resistance. Research from the Bowers laboratory and others established that combining a GHRH analogue with a GHRP produces synergistic GH pulses 2–10x larger than either alone. Clinical studies confirmed Mod GRF 1-29 produces a clean, physiological GH pulse pattern that preserves negative feedback. Independent pharmacokinetic studies established its ~30-minute half-life. The short half-life has been confirmed as advantageous for preserving pulsatility and preventing receptor desensitization compared to the DAC version.

View full research index →

Research Dosing

Typical Dose

100 mcg per dose, 2–3 times daily

Half-Life

~30 minutes (designed to match natural GHRH pulse window)

The standard dose is 100 mcg per injection, administered subcutaneously. It is always used in combination with a GHRP at a 1:1 ratio per injection: 100 mcg CJC-1295 no DAC + 100–200 mcg ipamorelin (or another GHRP) injected from the same syringe 2–3 times daily. The two peptides can be mixed in the same syringe safely. Optimal injection timing is: upon waking (fasted), pre-workout (45 min before training), and immediately before bed. The bedtime dose is most critical as it amplifies the natural overnight GH pulse. Avoid dosing within 2 hours of a high-carbohydrate meal. Typical cycle length is 8–16 weeks.
Open Dosage Calculator

Protocols

Classic GHRH + GHRP Protocol: CJC-1295 no DAC 100 mcg + Ipamorelin 200 mcg twice daily (morning and bedtime) for 12 weeks. Aggressive GH Protocol: CJC-1295 no DAC 100 mcg + GHRP-2 100 mcg 3x daily for 12–16 weeks (higher GH output but more hunger and water retention). Anti-Aging/Sleep Protocol: single nightly dose of CJC-1295 no DAC 100 mcg + Ipamorelin 200 mcg at bedtime only for 16–24 weeks.

Reported Side Effects

Side effects summarized from animal studies and researcher community observations. Educational purposes only — not medical advice.
Side effects mirror those of ipamorelin when the two are combined. Water retention is the most common complaint, particularly in the first 2–4 weeks. Mild joint stiffness and tingling in the hands can occur at higher GH levels. A brief head rush, lightheadedness, or temporary hypoglycemic sensation within 10–20 minutes of injection is common and typically resolves quickly. Fatigue and increased appetite may occur initially. Because CJC-1295 no DAC has a short half-life, it does not cause receptor desensitization over time, making it suitable for long cycles without diminishing returns.

Storage & Handling

Store lyophilized powder at 2–8°C (refrigerator) protected from light and humidity. Stable for up to 18 months in lyophilized form. After reconstitution with bacteriostatic water, store at 2–8°C and use within 28 days. Do not freeze reconstituted solution. A 2 mg vial reconstituted with 2 mL BAC water yields 1,000 mcg/mL (1 mcg per 0.001 mL on a U-100 syringe). Can be combined in the same vial as ipamorelin for convenience once both are reconstituted separately.